LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase IIIb VOLITION study demonstrating that 89% (n=129/145) of eligible treatment-naïve people living with HIV opted to switch to long-acting injectable Vocabria + Rekambys (branded as Cabenuva in the US Canada and Australia) following rapid viral suppression with daily Dovato (dolutegravir/lamivudine (DTG/3TC)). Additional re

NEWTOWN, Pa., July 14, 2025 /PRNewswire/ -- David Navazio, President and CEO of Gentell and Affiliated Companies, the largest vertically integrated wound care company in the world, announced his company's acquisition of ManukaMed, a leading manufacturer of honey-based wound dressings. ManukaMed is headquartered in New Zealand. The acquisition gives Gentell control of the only honey-based wound care product that is reimbursable by Medicare and other insurance organizations in the United States. M

BOSTON, July 14, 2025 /PRNewswire/ -- CDX Medical Technologies (CDX), a pioneer in extracorporeal membrane oxygenation (ECMO) pump innovation, today announced the successful close of its $2.5 million Series A funding round. The round was led by Joe Kiani, Founder of Masimo and a world-renowned health technology entrepreneur, with participation from leading industry executives and the CDX Board of Directors. Kiani, who also founded Willow Laboratories and co-founded Like Minded Labs, will join th

NASHVILLE, Tenn., July 14, 2025 /PRNewswire/ -- Tennessee Oncology, which treats nearly half of the cancer patients in the Volunteer State, today proudly opened the doors to patients at a new state-of-the-art cancer center at Elliston Place Plaza, 322 22nd Avenue North between Centennial Medical Center and Ascension Saint Thomas Midtown. The opening marks a major milestone in the organization's nearly 50-year legacy of delivering high-quality, compassionate cancer care throughout Tennessee. Sta

CHICAGO, July 14, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is proud to announce the three recipients of the 2025 FSR Early Career Fellowship Grant: William Lippitt, PhD, (University of Colorado Anschutz Medical Campus), Juan Carlos Quijano-Campos, RN, BSc (Hon), MSc (Hon) (King’s College London), and Paul Ettel, MD, (Medical University of Vienna). Each awardee will receive $150,000 in funding to advance their sarcoidosis-focused research and contribute to improved

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced the pricing of 22 million ordinary shares, par value $0.0001 per share, of the Company (the “Placement Shares”), at a price of HKD68.60 per share, in the offering by Dajun Yang Dynasty Trust, an affiliate of the Company’s

TWINSBURG, Ohio, July 14, 2025 /PRNewswire/ -- Xact Laboratories, a Biotech innovator in evidence-based medication guidance, has received a landmark United States Patent No.: US 12,354,724 B2, issued July 8, 2025, that will revolutionize pharmacogenomic and genetic efficacy data exchange. This milestone establishes Xact Laboratories' intellectual property rights over genetic testing data transmitted to pharmacy systems or provider electronic networks- which is a critical step toward establishin

SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co. (together with its debtor subsidiaries, the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, under Section 363 of the U.S. Bankruptcy Code. As par

OSLO, Norway, July 14, 2025 /PRNewswire/ -- The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the agenda were approved in accordance with the board of directors' proposals. A copy of the minutes from the EGM is attached to this notice and will also be made available on the Company's webpage . This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For further information, pl

Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings across the healthcare system by streamlining early-stage drug discovery, reducing wet lab dependency, and accelerating timelines.Beyond cost savings, Tevogen.AI leadership believes AI-driven drug discovery has the potential to generate billions in top line revenues for companies who are early adopters.With virology datasets curated and alpha model created, Tevogen.AI will now apply P